Tian Da Pharmaceutical (00455.HK) released its interim results, with a net loss attributable to shareholders of 33.23 million Hong Kong dollars, a year-on-year increase of 22.03%.

The Zhitong Finance and Economics APP reported that Tian Da Pharmaceutical (00455.HK) released its mid-term performance for 2025, with the group's revenue reaching 137 million Hong Kong dollars, a decrease of 12.45% year-on-year. The company's net loss attributable to shareholders widened by 22.03% to 33.237 million Hong Kong dollars, with a basic loss per share of 1.55 Hong Kong cents.